This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Renal Carnitine Transport Defect
Information about Renal Carnitine Transport Defect: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Renal Carnitine Transport Defect
Most recent studies have shown that Renal Carnitine Transport Defect shares some biological mechanisms with cardiac-hypertrophy, cardiomyopathies, cardiomyopathy-dilated, encephalopathies, fatty-liver, hyperammonemia, hypertrophy, hypoglycemia, inborn-errors-of-metabolism, metabolic-diseases, muscle-weakness, myopathy, reye-syndrome, steatohepatitis, steatosis, weakness.
Among the many pathways, these few ones have gauged particular interests from scientists studying Renal Carnitine Transport Defect, and have been seen in publications frequently: Aging, Cardiac Conduction, Carnitine Transport, Cell Cycle, Excretion, Fatty Acid Beta-oxidation, Fatty Acid Oxidation, Fatty Acid Transport, Gluconeogenesis, Glycolysis, Hexose Transport, Immune Response, Lipid Storage, Localization, Organic Cation Transport, Oxidative Phosphorylation, Pathogenesis, Secretion, Transport, Urea Cycle
Quite a number of genes have been found to play important roles in Renal Carnitine Transport Defect, such as CPT2, DAG1, DNAH5, DNAI1, ETFA, ETFB, ETFDH, IFT81, JUN, JUND, PCBD1, SCD, SLC22A4, SLC22A5. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.